In conclusion, we found no association between CYP2C19 and CYP2D6 polymorphisms on treatment effect by cyclophosphamide, thalidomide and bortezomib in patients with multiple myeloma after HDT with stem cell support. The gene discussed is CYP2D6; the disease is plasma cell myeloma.